NuProbe Funding: How Much Did They Raise & Key Investors

How Much Did NuProbe Raise?
Funding & Key Investors

NuProbe, a prominent player in the genomics and molecular diagnostics sector, has successfully secured a total capital infusion of $58.3M. This latest financial milestone, characterized by a $5.3M strategic investment, underscores the firm's robust growth trajectory and its commitment to advancing high-sensitivity sequencing technologies. By consistently attracting significant backing, the company has solidified its position as a critical innovator in the global precision medicine landscape.

The funding history reflects a disciplined expansion strategy, beginning with its initial Series A round in 2018 and progressing through subsequent rounds of financing. This capital accumulation provides the necessary runway to scale operations across its key hubs in Houston and China, ensuring that its proprietary diagnostic platforms remain at the forefront of clinical research and molecular analysis.

What is NuProbe?

NuProbe

Business Services

Research & Development

NuProbe operates at the intersection of biotechnology and advanced diagnostics, specializing in molecular technologies that enhance the sensitivity of mutation detection and copy number variations by more than 10-fold. By focusing on Research Use Only applications, the company provides essential tools for researchers aiming to decode complex genetic data with unprecedented accuracy. Its global footprint, spanning the United States and China, allows NuProbe to leverage diverse talent pools and market insights to drive its mission of making disease state information more accessible and actionable for the medical community.

How much funding has NuProbe raised?

NuProbe has raised a total of $58.3M across 3 funding rounds:

2018

Series A

$11M

2021

Unspecified

$42M

2022

Unspecified

$5.3M

Series A (2018): $11M, investors not publicly disclosed

Unspecified (2021): $42M led by Panlin Capital, Juming Capital, Tuobang Capital, Biotrack Capital, Yonghua Capital, and Taifu Capital

Unspecified (2022): $5.3M, investors not publicly disclosed

Key Investors in NuProbe

Panlin Capital

A venture capital firm focused on identifying and supporting high-growth technology and healthcare enterprises in the Chinese market.

Juming Capital

An investment firm specializing in strategic equity financing for emerging companies within the life sciences and biotechnology sectors.

Tuobang Capital

A private equity group that provides growth capital to innovative firms, with a strong emphasis on technological advancement and market scalability.

What's next for NuProbe?

With the recent influx of capital, NuProbe is well-positioned to accelerate its research and development initiatives, particularly in refining its sequencing sensitivity protocols. The strategic focus will likely shift toward expanding its product portfolio and deepening its market penetration in the molecular diagnostics space. As the company continues to bridge the gap between raw genetic data and clinical utility, it remains a pivotal entity for stakeholders interested in the future of precision medicine and the ongoing evolution of diagnostic infrastructure.

See full NuProbe company page

See More Financial Insights